Naloxegol Oxalate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319933

CAS#: 1354744-91-4 (oxalate)

Description: Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified) derivative of α-naloxol. Specifically, the 5-α-hydroxyl group of α-naloxol is connected via an ether linkage to the free hydroxyl group of a monomethoxy-terminated n=7 oligomer of PEG.

Price and Availability


USD 90
USD 450
USD 3250

USD 150
USD 950
USD 5450

USD 250
USD 1750
USD 8650

Naloxegol Oxalate, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319933
Name: Naloxegol Oxalate
CAS#: 1354744-91-4 (oxalate)
Chemical Formula: C36H55NO15
Exact Mass:
Molecular Weight: 741.828
Elemental Analysis: C, 58.29; H, 7.47; N, 1.89; O, 32.35

Related CAS #: 1354744-91-4 (oxalate)   854601-70-0 (free base)  

Synonym: NKTR-118; NKTR 118; NKTR118; AZ-13337019; AZ13337019; AZ 13337019; EGylated naloxol; Naloxegol Oxalate; trade names Movantik and Moventig.

IUPAC/Chemical Name: (4R,4aS,7S,7aR,12bS)-7-((2,5,8,11,14,17,20-heptaoxadocosan-22-yl)oxy)-3-allyl-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol oxalate


InChi Code: InChI=1S/C34H53NO11.C2H2O4/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2;3-1(4)2(5)6/h3-5,28-29,32,36-37H,1,6-25H2,2H3;(H,3,4)(H,5,6)/t28-,29+,32-,33-,34+;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information


1: Al-Huniti N. Reply to: Letter to the Editor "Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol". J Clin Pharmacol. 2016 Apr;56(4):508. doi: 10.1002/jcph.674. PubMed PMID: 26954553.

2: Ruan X. The Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol. J Clin Pharmacol. 2016 Apr;56(4):506-7. doi: 10.1002/jcph.651. PubMed PMID: 26954552.

3: Naloxegol (Movantik) for Opioid-Induced Constipation. JAMA. 2016 Jan 12;315(2):194-5. doi: 10.1001/jama.2015.17459. PubMed PMID: 26757469.

4: Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. J Clin Pharmacol. 2015 Dec 17. doi: 10.1002/jcph.693. [Epub ahead of print] PubMed PMID: 26678015.

5: ▼Naloxegol for opioid-induced constipation. Drug Ther Bull. 2015 Dec;53(12):138-40. doi: 10.1136/dtb.2015.12.0369. PubMed PMID: 26660436.

6: Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015 Oct;3(5):471-80. doi: 10.1177/2050640615604543. PubMed PMID: 26535126; PubMed Central PMCID: PMC4625753.

7: Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther. 2015 Sep 28;57(1478):135-7. Review. PubMed PMID: 26393826.

8: Corsetti M, Tack J. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. Drugs Today (Barc). 2015 Aug;51(8):479-89. doi: 10.1358/dot.2015.51.8.2364896. Review. PubMed PMID: 26380386.

9: Bui K, She F, Hutchison M, Brunnström Å, Sostek M. Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. Int J Clin Pharmacol Ther. 2015 Oct;53(10):838-46. doi: 10.5414/CP202276. PubMed PMID: 26329350; PubMed Central PMCID: PMC4564822.

10: Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol. 2016 Jan;81(1):89-100. doi: 10.1111/bcp.12756. Epub 2015 Oct 27. PubMed PMID: 26317320; PubMed Central PMCID: PMC4693583.

11: Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015. PubMed PMID: 26312011; PubMed Central PMCID: PMC4544149.

12: Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol. 2016 Apr;56(4):497-505. doi: 10.1002/jcph.613. Epub 2015 Nov 9. PubMed PMID: 26248047.

13: Hussar DA, Jeon MM. Naloxegol oxalate, pirfenidone, and nintedanib. J Am Pharm Assoc (2003). 2015 Jul-Aug;55(4):461-3. doi: 10.1331/JAPhA.2015.15523. PubMed PMID: 26161491.

14: Jones R, Prommer E, Backstedt D. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation. Am J Hosp Palliat Care. 2015 Jul 6. pii: 1049909115593937. [Epub ahead of print] PubMed PMID: 26150678.

15: Bruner HC, Atayee RS, Edmonds KP, Buckholz GT. Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res. 2015 Jun 12;8:289-94. doi: 10.2147/JPR.S61326. eCollection 2015. Review. PubMed PMID: 26109876; PubMed Central PMCID: PMC4472065.

16: Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: removal of naloxegol from control. Final rule. Fed Regist. 2015 Jan 23;80(15):3468-70. PubMed PMID: 25730920.

17: Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75(4):419-25. doi: 10.1007/s40265-015-0357-2. Review. PubMed PMID: 25666542.

18: Corsetti M, Tack J. Naloxegol , a new drug for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2015 Feb;16(3):399-406. doi: 10.1517/14656566.2015.991306. Epub 2014 Dec 13. Review. PubMed PMID: 25496063.

19: Leonard J, Baker DE. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5. doi: 10.1177/1060028014560191. Epub 2014 Dec 3. Review. PubMed PMID: 25471070.

20: Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014 Sep 19;7:345-58. doi: 10.2147/CEG.S52097. eCollection 2014. Review. PubMed PMID: 25278772; PubMed Central PMCID: PMC4179399.